Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03938987
Title Anti-CD19, Dual Co-stimulatory (4-1BB, CD3zeta) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL) (ACIT001/EXC002)
Acronym ACIT001/EXC002
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors University of Alberta
Indications
Therapies
Age Groups: adult | child | senior
Covered Countries CAN

Facility Status City State Zip Country Details
Foothills Medical Centre NOT_YET_RECRUITING Calgary Alberta T2N2T9 Canada Details
Tom Baker Cancer Centre NOT_YET_RECRUITING Calgary Alberta T2N4N2 Canada Details
Alberta Children's Hospital NOT_YET_RECRUITING Calgary Alberta T3B6A8 Canada Details
Cross Cancer Institute RECRUITING Edmonton Alberta T6G1Z2 Canada Details
Stollery Children's Hospital NOT_YET_RECRUITING Edmonton Alberta T6G2B7 Canada Details
University of Alberta Hospital RECRUITING Edmonton Alberta T6G2B7 Canada Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field